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INTRODUCTION
GM1-gangliosidosis and Morquio B disease are
autosomal recessive lysosomal storage diseases caused
by primary defects of theGLB1 gene, which is located
on chromosome 3 p 21.33 (1,2). GM1-gangliosidosis
comprises neurosomatic clinical phenotypes ac-
companied by the accumulation of GM1-ganglioside
in the central nervous system (CNS) and β-galactosyl
glycoconjugates in visceral organs.Morquio B disease
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is characterized by generalized skeletal dysplasia
without CNS involvement. The patients exhibit reduced
catalytic activity toward keratan sulfate and oligo-
saccharides but normal activity toward GM1-ganglioside.
These patients may also exhibit cardiac-valve mal-
formations, aortic stenosis, and intimal thickening
in the coronary arteries and pulmonary artery (3, 4).
Lysosomal protective protein/cathepsin A (PPCA;
EC 3.2.1.14) is a serine carboxypeptidase that forms
a high molecular weight complex with β-galactosidase
(β-Gal ; EC 3.2.1.23) and neuraminidase-1 (NEU1;
EC 3.2.1.18), and it stabilizes the former enzyme and
activates the latter one in lysosomes (protective
function). A genetic defect of PPCA causes an autoso-
mal recessive inherited metabolic disorder, galac-
tosialidosis, associated with a combined deficiency of
cathepsin A, β-Gal, andNEU1 and neurosomatic clinical
manifestations (5).
Sialidosis is an autosomal recessive metabolic
inborn error caused by a genetic defect of NEU1, which
is accompanied by accumulation in tissues and urinary
excretion of sialyloligosaccharides and neuroso-
matic phenotypes (6).
Elastic fibers in connective tissues and blood vessel
walls aremade of polymeric tropoelastin andare placed
on a scaffold of microfibrils consisting of glycoproteins
(e.g. fibrillins and microfibril-associated glycopro-
teins)(7, 8). Several functional proteins, including elastin-
binding protein (EBP) as a tropoelastin chaperone
and lysyl oxidase involved in cross-linking, have also
been demonstrated to contribute to elastic fiber
formation (9 -12). Impaired elastogenesis has been
reported in various human diseases, includingMarfan
syndrome (13), William syndrome (14), and Costello
syndrome (15, 16), accompanied by connective tissue
abnormalities and cardiovascular manifestations.
Hinek et al. have demonstrated that an enzymatically
inactive, alternatively spliced variant of the GLB1
gene product functions as an EBP to facilitate in-
tracellular transport and extracellular assembly of
tropoelastin into elastic fibers (17,18). The 67-kDa
EBP with a different stretch of 32 amino acids from
β-Gal has also been reported to be a major component
of the non-integrin cell surface receptor complex
composed of PPCA and NEU1 for elastic peptides
involved in the signal transduction for proliferation
and migration of fibroblasts, smooth muscle cells,
chondroblasts, leukocytes, and certain cancer cell
types (12, 19, 20). In recent years, Mochizuki et al .
have also hypothesized that the 67-kDa EBP might
associate with PPCA and NEU1 to form a secondary
complex different from the lysosomal multien-
zymic complex consisting of β- Gal, PPCA and
NEU1, and the secondary complex might interact
with an intracellular signaling system including G-
protein coupled receptor and effectors (21). Addi-
tionally, Malvagia et al. reported that newPPCA gene
mutations (c60delG and IVS 2＋1 G>T) that lead to
a frameshift and a premature stop codon, identi-
fied in a galactosialidosis patient, reduce the 67-
kDa EBP protein expressed in the patient’s fibro-
blasts accompanied by an absence of elastic fibers
deposition (22, 23), suggesting the PPCA might be
essential for the integrity of the secondary complex.
The GLB1, PPCA and NEU1 gene mutations have
been identified in patients with these lysosomal enzyme
deficiencies, and the genotype-phenotype relationship
has been analyzed (5, 24-27). On the other hand,
dysfunction of EBP as an alternative pathogenic
mechanism has been proposed to contribute to the
connective tissue and cardiovascular malformations
in β- Gal deficiencies as well as Costello syndrome
(19, 28-30), although the relation between the defect
in EBP and the abnormalities has not been established
yet.
In this study, we analyzed elastic fiber formation
in cultures of skin fibroblasts from patients with β-Gal,
PPCA and NEU 1 deficiencies as well as Costello
syndrome, and discuss the relation between the effects
of each gene mutation on the expression of EBP and
elastogenesis.
METHODS
Human skin fibroblasts derived from patients and
control subjects ; F430, a juvenile GM1-gangliosido-
sis with missense mutations R201C/R201C in the
GLB1 gene (31) ; F435, a juvenile GM1-gangliosidosis
with R201H/N318H (32) ; F350, a Morquio B dis-
ease with W273L/R482H in the GLB1 gene (32) ; F
351, a Morquio B disease with W273L/W509C (33) ; F
451, a Morquio B disease with W273L/W273L (32) ;
F622, a galactosialidosis with a splicing mutation
in the PPCA gene (IVS7+3aA/IVS7+3a)(unpublished
case); F319, type1 sialidosis with missensemutations
in the NEU1 gene (V217M/G243R) (27); F642, Costello
syndrome(unpublished case) ; and F592, a normal
subject, were cultured in Ham’s F-10 medium sup-
plemented with 10% fetal bovine serum (FBS) and
antibiotics at 37℃ under 5% CO2. The research was
carried out in accordancewith theDeclarationofHelsinki
of the WorldMedical Association, and was approved
by the ethical committee of the institution in which
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the work was performed.
Elastic fiber formation on the surface of skin fibroblasts
was assayed as immunofluorescence with the anti-
fetal bovine tropoelastin serum (Elastin Products
Company, Inc., Owensville,MO). The fibroblasts were
plated on 8-well chamber slides (Nunc., Pittsburgh,
PA), and then cultured for 10 days to confluency. The
cells were fixed with cold 2% paraformaldehyde/
phosphate buffered-saline (PBS) overnight at 4℃,
and then immunostained by a two-step incubation
method ; first with a 1 : 500 dilution of the anti-fetal
bovine tropoelastin serum, and then with a 1 : 1000
dilution of goat anti-rabbit IgG-F(ab’)2 fragment
conjugated with rhodamine (Biosource International,
Camarillo, CA). After inclusion, elastic fiber formation
was observed under a confocal laser scanning mi-
croscope (LSM5Pascal-V2.8 ; Zeiss, Oberkochen,
Germany). Morphometric analysis of the immunostained
fibroblasts was also performed by standard digital
imaging software attached to the confocal microscopic
system. The relative amount of the deposited elastic
fiber over the fibroblast was expressed as the im-
munofluorescence intensity index in each image.
Relative fluorescence intensity was graded, ranging
from 0 to 255 in this system. The fluorescence intensity
linearly correlated with the number of pixels showing
a positive signal. In each optic field, the immunofluorescent
area with more than 100 intensity was estimated
as elastic fiber-positive area, and the relative index
(mean±SD) was expressed as a percentage of the
total optical field area. The number (n) of optical fields
ranged from 2 to 7.
For RT-PCR analysis, fibroblasts (approx. 5×105 on
60-mm plastic dishes) were rinsed with cold PBS,
and then homogenized manually in 1 ml of TRIZOL
reagent (Invitrogen, Carlsbad, CA) on ice. RNA was
isolated according to the manufacturer’s protocol.
Briefly, 0.2 ml of CHCl3 was added to the homo-
genate, and followed by centrifugation at 20,600× g
for 15 min. An equal volume of 2-propanol was added
to the resultant supernatant to precipitate RNA.
After centrifugation, the pellet was rinsed with 75%
ethanol/diethylpyridylchloride (DEPC)-treated water,
and then dried. The pellet was dissolved in an
appropriate volume of DEPC-treated water as the total
RNA fraction. For reverse transcription (RT), 2 µg
RNA from each sample was transcribed at 37℃ for
1 h in the presence of 200U of Molony leukemia
virus reverse transcriptase (Promega, Madison, WI),
Oligo(dT)12-18 primer (Invitrogen), 0.5mMdNTPs and
50U of RNaseOUT (Invitrogen). The PCRs for β-Gal,
EBP and β- actin were performed within the linear
range of amplification using the following selective
primer sets: β-Gal (Accession No. M27507), forward
5’-GGACCGGCTGCTGAAGATGA-3’, reverse
5’-TTGATGGGCCCAGAGGGACA-3’; EBP (Accession
No. M27508), forward
5’-CCATCCAGACATTACCTGGC-3’, reverse
5’-TTGATGGGCCCAGAGGGACA-3’; β-actin (Accession
No. NM 001101), forward
5’-GACAACGGCTCCGGCATGTG-3’, reverse 5’-CCT
TCTGCATCCTGTCGGCA-3’.
β- actin was amplified for 30 cycles, and β- Gal and
EBP for30～35cycles.ThePCRproductswere analyzed
by 1.5% agarose gel electrophoresis and stained
with ethidium bromide (Sigma). As a control, RTwas
also performed in the absence of Molony leukemia
virus reverse transcriptase. In another experiment,
plasmid DNAs including human β- Gal and EBP
cDNAs, respectively, were used as templates as
positive controls.
Real-time PCR analysis of human β- Gal and
EBPmRNA relative to β-actin mRNA was performed
by means of the SYBR Green I (Roche, Mannheim,
Germany) assay for comparison. The β-Gal, EBP and
β-actin mRNAs were amplified by using a GeneAmp
5700 Sequence Detection System (PE Applied
Biosystem, Foster City, CA, USA) in the presence
of cDNAs, as templates, prepared from the fibroblasts,
as described above, 0.25 mM each primer, a 1/10
vol. of 10×FastStart DNA master SYBR Green I,
and 1.5 mM MgCl2 using the following protocol :
95℃ for 10 min, then 45 cycles of denaturation at 95℃
for 30 s, annealing at 60℃ for 30 s, and extension at
72℃ for 60 s. For standardization of quantification,
β-actin was amplified simultaneously. The change of
reporter fluorescence in each reaction tube was
monitored by a GeneAmp 5700 Sequence Detection
System. The threshold cycle (Ct) for each mRNA
was determined as PCR cycle number at which the
reporter fluorescence reached above 10-fold of the
standard deviation of the baseline signal. The fold
change of the EBP or β- Gal mRNA relative to that
of β-actin was determined as follows :
Fold chang = 2-ddCt , where dCt=Ct EBP or β-Gal - Ct β - actin,
and ddCt=dCt target - dCt F592
β-Gal activity was measured in cell extracts of
cultured skin fibroblasts using 4-methylumbelliferyl
β-D-galactoside (34). Protein determination was
performed with the DC protein assay kit (Bio-Rad
Laboratories, Richmond, CA) with bovine serum
albumin (BSA) as the standard.
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RESULTS
We have studied five patients from unrelatede the
juvenile form of GM1-gangliosidoisis, and three
patients had Morquio B disease. We also examined
one patient affected by galactosialidosis (a PPCA
deficiency), and one patient with sialidosis (a NEU1
deficiency). Table 1 summarizes the clinical phe-
notypes, intracellular β-Gal activities and geno-
types. A marked decrease in β-Gal activity was
confirmed in the cases of GM1-gangliosidosis and
Morquio B disease, and a partial β-Gal deficiency
was observed in the galactosialidosis with a splicing
mutation in thePPCA gene allele (IVS7＋3a/IVS7＋3a),
based on the enhanced proteolytic degradation. In
contrast, the β-Gal activities in fibroblasts from the
patients with Costello syndrome and sialidosis with
missense mutations in the NEU1 gene allele (V217
M/G243R) were normal.
Figure 1 shows the location of point mutations in
GLB gene identified in the present GM1-gangliosidosis
andMorquio B disease cases. TheGLB1 genemutations
causing W273L, N318H, R482H and W509C amino
acid substitutions located in the exon 8, 14 and 15,
respectively, possibly have effects on expression and
functions of the mutant EBP while those causing the
R201C and R201H substitutions located in the exon 6
impossibly have effects on the EBP expression and
functions because the mutated portion should be
spliced out in the resultant EBP mRNA. Therefore,
normal EBP expression in the juvenile GM1-
gangliosidosis cases (F430 and F435) with the
GLB1 genotypes (R201C/R201C and R201H/N318H,
respectively) is expected, although the difference
in gene dosage effect on normal EBP expression
might be exhibited between the two cases.
As shown in Fig. 2a, immunofluorescence analysis
with anti-bovine tropoelastin antibodies that cross-
react with the human counterpart revealed that
extracellular elastic fiber formation occurred in the
fibroblasts from all the patients affected with β-Gal
deficiencies, including the juvenile forms of GM1-
gangliosidosis (F 430 and F 435), and the Morquio
B syndrome (F350, F351 and F451), as well as in
the normal subject (F592), although there might be
a slight shape change of elastic fiber in the F451 case.
The fibroblasts (F430) from the GM1-gangliosidosis
patient with a homozygous mutation causing amino
acid substitution R201C showed reasonable elastic
fiber formation, this substitution being absent in
the amino acid sequence of EBP and not having an
effect on the normal EBP function. The fibroblasts
(F435) from the GM1-gangliosidosis patient with a
compound heterozygous mutated allele causing
amino acid substitutions R201C and N318H also
exhibited the elastic fiber formation. A significant
Fig. 1．Schematic representation of the human β-galactosidase (GLB1) gene containing the relative position of the sixteen exons and
listing the identified mutations in the present clinical cases. Amino acid numbers spliced out from the amino acid sequence of the human
β- galactosidase precursor protein are also indicated
Table 1. Phenotypes and genotypes of Lysosomal enzyme
dificiencies and Costello syndorome
case Phenotype Genotype % ofnormal activitya)
F 592
F 350
F 351
F 451
F 430
F 435
F 319
F 622
F 642
Normal
Morquio B
Morquio B
Morquio B
Juvenile GM 1-gangliosidosis
Juvenile GM 1-gangliosidosis
Sialidosis(Type 1)
Galactosialidosis
Costello syndrome
W 273 L/R 482 H
W 273 L/W 509 C
W 273 L/W 273 L
R 201 Cb)/R 201 C
R 201 Hb)/N 318 H
V 217 Mc)/G 243 Rc)
IVS 7＋3 ad)/IVS 7＋3 ad
100
2.1
3.6
3.1
2.8
3.1
100
19.6
86.6
a) Relative β-Gal activity to that of nomal subject was indicated.
b) The amino acid position is splicedout inEBPamino acid sequence.
c) The genotype for NEU1 gene is indicated.
d) The genotype for PPCA gene is indicated.
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gene dosage effect on fiber formation was not also
observed (F430 and F435). We also examined the
elastic fiber formation in the fibroblasts derived
from an infantile (24, 25) and a juvenile (24, 25) GM1-
gangliosidosis case, in which the GLB1 gene mu-
tations and genotypes were not determined, and
also demonstrated the normal elastogenesis in these
cases (data not shown). The patients affected with
Morquio B disease comprised a homozygote and
compound heterozygotes withmutated alleles causing
W273L/W273L, W273L/R482H and W273L/W509C
amino acid substitutions, respectively. In particular,
the fibroblasts (F451) from the Morquio B patient
with the W273L/W273L allele exhibited elastic fiber
formation. Moreover, fibroblasts from the patients
with galactosialidosis and sialidosis also showed
extracellular elastic fibers (F622 and F319) as well
as a normal subject (F592). In contrast, elastic fiber
formation was hardly observed in fibroblasts from
the patient with Costello syndrome (F642).
We also performed semi-quantitative evaluation for
elastogenesis by means of the immunofluorescent
imaging. As shown in Fig.2b, the degree of elastic
fiber formation expressed as the relative im-
munofluorescence index was not significantly
changed among normal subject and the patients
with GM1-gangliosidosis, Morquio B disease,
galactosialidosis and sialidosis, while the index value
of Costello syndrome was very low.
We next examined the differential expression of
mRNAs encoding β-Gal precursor protein and EBP,
respectively, by RT-PCR using selective primers that
discriminate each alternative splicing product. As
shown in Fig. 3, significant transcriptional expression
of β-Gal precursormRNAwas confirmed in fibroblasts
from patients with GM1-gangliosidosis andMorquio
B disease as well as in controls, including ones
with galactosialidosis and sialidosis (panel a), as
previously reported (24, 25). On the other hand, a
significant level of EBP mRNA was observed in all
of the fibroblasts from patients affected with GM1-
gangliosidosis and Morquio B disease (panel a).
Fig. 2．Immunofluorescence analysis for
elastic fibers in fibroblasts. (a) Elastic fiber
formation was observed under a fluorescence
microscope. Normal control, F 592 ; juvenile
GM1-gangliosidosis, F430 and F435 ;Morquio
B disease, F350, F351 and F451; juvenile/adult
galactosialidosis, F 622 ; type I sialidosis,
F319;Costello syndrome, F642. Bar, 20 mm.
(b) Morphometric analysis of elastic fiber
formation by means of anti-tropoelastin an-
tibody. In each optic field, the immunofluo-
rescent area with more than 100 intensity was
estimated as elastic fiber-positive area, and
the relative index (mean±SD) was expressed
as a percentage of the total optical field area.
n=2～7.
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Expression of EBP was also observed in the cells
from the patient with Costello syndrome (panel b).
To evaluate the semi-quantitative expression of β-
Gal and EBPmRNAs in the fibroblasts with lysosomal
enzyme deficiencies and Costello syndrome, the
gene expression ratios of β-Gal and EBP mRNAs
relative to β-actin, respectively, were alsomeasured by
real-time PCR analysis. As shown in Figure 4a, the
relative fold change in expression level of EBPmRNA
in the fibroblasts with lysosomal enzyme deficiencies
and Costello syndrome ranged from0.4 to 1.3, compared
to that of normal subject (F592). Figure 4b shows
the results for β-Gal mRNA. The relative fold change
ranged from 0.7 to 2.2 among the fibroblasts.
The expression levels of EBP and β-Gal mRNAs
did not correlate with the elastic fiber formation in
the fibroblasts, although those of EBP mRNA in
the GM1-gangliosidosis cases (F430 and F435)
and a sialidosis case (F319) were about half of the
normal control. These results suggest that there
might not be a remarkable defect in the expression
of EBP mRNA in the present β-Gal deficiencies as
well as Costello syndrome.
DISCUSSION
The humanGLB1 gene encodes two gene products
(1, 2). In human fibroblasts, two kinds are synthesized;
one is a larger (2.4 kb) and more abundant mRNA
encoding the full length lysosomal β-Gal precursor
protein of 677 amino acids, and the other is a minor
form (2.0 kb) produced through alternative splicing
(whereby exons 3, 4, and 6 are deleted) which encodes
an enzymatically inactive variant of 546 amino acids
(35). The former GLB1 product is co-translationally
modified into a glycosylated 88-kDa precursor and
then processed into a 64-kDa mature enzyme that
associates with PPCA ; and NEU1 to form a stable
multienzymic complex in lysosomes (5, 36), which
Fig. 3．Expression analysis for EBP mRNA in fibroblasts by RT-PCR. (a) RT-PCR for EBP, β- Gal and β- actin mRNAs was
performed as described under“Methods”. Lane 1, plasmid DNA carrying the β- Gal cDNA as a positive control ; lane 2, plasmid
DNA carrying the EBP cDNA as a positive control ; lane 3, F 592 ; lane 4, F 430 ; lane 5, F 435 ; lane 6, F 350 ; lane 7, F 351 ; lane
8, F 451 ; lane 9, F 319 ; lane 10, F 622. (b) RT-PCR analysis of fibroblasts (F 642) derived from the Costello syndrome patient.
Lanes 1 and 2, F 642 in the presence and absence of reverse transcriptase, respectively ; lanes 3 and 4, F 350 in the presence and
absence of reverse transcriptase, respectively.
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degrades glycoconjugates carrying β-galactose
residues at their non-reducing termini, including
GM1-ganglioside, keratan sulfate, and glycopro-
teins(1). The latter product is the 67-kDa EBP that
functions as a molecular chaperon for tropoelastin
in elastogenesis (17, 18). In recent years the EBP
has also been suggested to form a cell surface
receptor complex for elastic peptides with NEU1
and PPCA (20) that might be involved in cell pro-
liferation and migration via signal transduction
coupled with G-proteins (21).
GM1-gangliosidosis caused by the GLB1 gene
mutation is classified into three clinical forms : in-
fantile (type 1), late infantile/juvenile (type 2), and
adult/chronic (type 3). The most severe infantile
patients develop rapidly progressive CNS involvement,
skeletal abnormalities, and visceromegaly. A few
patients have also been reported to show cardio-
myopathy (3, 4, 37, 38). The late infantile/juvenile
form is characterized by slowly progressive neuro-
logical symptoms. The rare adult/chronic form shows
mild extrapyramidal manifestations, such as dystonia
(1). On the other hand, Morquio B disease patients
develop generalized skeletal dysplasia without CNS
involvement. These phenotypes are believed to be
governed by the kind ofGLB1mutationand the residual
β-Gal activity toward natural substrates. It has
been reported that impaired elastogenesis might
be caused by a genetic defect of 67-kDa EBP in the
β-Gal deficiencies, includingGM1-gangliosidosis and
Morquio B disease, which should be responsible for
some specific clinical manifestations in these dis-
orders, including cardiac involvement and dys-
functions in connective tissues (19, 29).
However, we demonstrated in this study that
significantly impaired elastogenesis was hardly
observed in cultured skin fibroblasts derived from the
six examined patients affected by β-Gal deficiencies,
including infantile and juvenile GM1-gangliosidosis
as well as Morquio B disease. Among the GM1-
gangliosidosis patients, it may be reasonable that
the two cases with the R201C/R201C and R201H/
N482H mutations exhibited normal elastic fiber
formation because the codon encoding the R 201
residue present in the exon 6 should have been spliced
out from the wild-type EBP mRNA, which does not
prevent the expression of normal EBP derived
from at least a GLB1 gene allele. On the other hand,
the three of the examined Morquio B disease cases
had the genotypes W273L/W273L, W273L/R482H
andW273L/W509C that involve in the coding region
of EBP, respectively. These fibroblasts with Morquio
B disease also showed elastic fiber formation, although
difference in the shape of elastic fiber was observed
in the F451 fibroblasts with theW273L/W273L genotype.
However, the difference was thought due to the cellular
state of the F451 cells rather than genetic defect.Mecham
R.P. suggested that elastin production should be extremely
unstable in vitro culture system and caremust be taken
to adjust culture conditions to optimize for elastin
production, including cell density, passage number
and concentration of FBS, although the elastin phenotype
shows greater stability in dermal fibroblasts in culture
than most other cell types including vascular smooth
muscle cells and ligament fibroblasts (39). We also
revealed that there was a significant amount of EBP-
specific mRNA in skin fibroblasts from the pa-
tients with β- Gal deficiencies. These results sug-
gested that theGLB1 gene mutations identified in the
present cases might neither cause the defect in EBP
mRNA expression nor the dysfunction of EBP leading
to impaired elastogenesis in cultured skin fibro-
blasts.
Costello syndrome is a connective tissue disorder
associated with sparse, thin, and fragmented elastic
fibers in tissues, and characterized by polyhydramnios,
a severely short stature, and a distinctive appearance
Fig. 4．Semi-quantitative evaluation of EBP and β- Gal mRNAs
expressed in fibroblasts. Relative fold changes for expression of
(a) EBP and (b) β- Gal mRNAs against β- actin mRNA were
measured by quantitative RT-PCR as described under“Methods”.
Column 1, F 592 ; column 2, F 430 ; column 3, F 435 ; column
4, F 350, column 5, F 319 ; column 6, F 622.
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with craniofacial and dermatological manifestations,
including soft skin, curly hair, hyperextensibility
of the digits, pigmented nevi, vascular birthmarks
and papillomata. (15, 16). About 60% of the patients
also develop various cardiac abnormalities. We observed
remarkably impaired elastic fiber formation in fibro-
blasts derived from the present Costello syndrome
case.
Recently, Hinek et al . has reported that some
proteoglycans regulate elastic fiber formation in
fibroblasts via EBP shedding on the cell surface
(28, 30). The“lectin-like”domain of EBP has been
suggested to contribute to the regulation of assembly-
disassembly between EBP and tropoelastin through
binding the β-galactosugar-bearing moieties on the
extracellular glycoconjugates, such as microfibrillar
glycoproteins, and glycosaminoglycans including
chondroitin sulfate and dermatan sulfate (28, 30,
40). The W273 residue of the human EBP is one of
the conserved amino acids in the“lectin-like”domain
putatively involving in binding to β-galactosugar-bearing
glycoconjugates. However, we demonstrated the
elastic fiber formation in fibroblasts derived from
the Morqiuo B disease patient with the W273L/W
273L genotype, while the elastic fiber formation in
fibroblasts derived from the present Costello syn-
drome patient was impaired. These results suggest
the W273L substitution in the EBPmight have little
influence on interaction with an extracellular gly-
cosaminoglycan carrying β-galactose residues and
EBP shedding.
We showed in this study that elastogenesis in skin
fibroblasts derived from patients with galactosialidosis
and sialidosis was also not significantly impaired.
Galactosialidosis, a PPCA deficiency, is classified
into three clinical groups, that is, a severe early infantile
form, a late infantile form and a juvenile/adult form
(5, 26). The present galactosialidosis patient with
the homozygous PPCA gene allele (IVS7＋3A/IVS
7＋3A) causing splicing mutation is the most typical
for the juvenile/adult Japanese cases, in which the
expression level of normal PPCAmRNAwas reported
to be about 10% of that expressed in normal fibroblasts
(26). Therefore, a small amount of PPCA protein
also exists in the galactosialidosis case, that is considered
enough for normal elastogenesis in the skin fibroblasts.
The clinical phenotypes of sialidosis are classified
in two major groups according to the age of onset
and severity: late-onset type 1 sialidosis is a relatively
mild form characterized by macular cherry-red spots
andmyoclonus, and early infantile-onset type 2 sialidosis
is a severe condition distinguished by the appearance
of dysmorphicmanifestations in addition to neurological
symptoms and cherry-red spots. Apparently normal
elastogenesis was also observed in the fibroblast derived
from a mild type1 sialidosis case with the compound
heterozygous NEU1 gene allele (V217M/G243R
substitutions). Our previous study showed a small
amount of the NEU1 product with V217M substitution
and a slight residual enzyme activity were expressed
from the mutated NEU1 allele, that might determine
the mild phenotype of the type 1 sialidosis patient,
while the G243R product hardly exhibited the normal
NEU1 functions (27). These results also suggested
that at least these amino acid substitutions in NEU1
product might not significantly affect the elastic
fiber formation in the sialidosis fibroblast.
Thus, the biological and clinical effects of functional
expression of the 67-kDa non-integrin EBP was
demonstrated to vary on β-Gal deficiencies, the related
genetic diseases and Costello syndrome. These findings
also suggest that putative dysfunction of EBP and
secondary complex with PPCA and NEU1 might
not be a dominant cause of impaired elastogenesis
at least in skin fibroblasts derived from the patients
with these deficiencies. Further detail and careful study
is necessary to elucidate the difference in elastogenesis
among these diseases as well as the interaction
among the components (EBP, PPCA and NEU1) of
the putative secondary complex involving in the elastic
fiber formation.
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